The G250E mutation is one of the common bcr-abl mutations that limits Gleevec effectiveness, so a change is necessary. Both Sprycel (Dasatinib) and Tasigna (Nilotinib) work well against it. From what I have seen, Sprycel worked somewhat better in clinical trials for this mutation (see 2nd article below). Sprycel may be a better choice since it binds to bcr-abl differently than Gleevec, while Tasigna binds similarly to Gleevec, just more strongly (an over- simplification, but maybe useful).
Here is a good article on the resistance issue: http://asheducationbook.hematologylibrary.org/cgi/content/full/2007/1/371 Here is an article with a chart showing overall mutation response during a clinical trial of Sprycel and Tasigna (see last line of the chart on 4th page): http://www.communityoncology.net/journal/articles/0308519.pdf --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---
